Hsbc Holdings PLC purchased a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 38,583 shares of the company's stock, valued at approximately $481,000.
A number of other large investors also recently bought and sold shares of DAWN. R Squared Ltd bought a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $31,000. Tower Research Capital LLC TRC increased its position in Day One Biopharmaceuticals by 911.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company's stock valued at $135,000 after buying an additional 9,603 shares in the last quarter. E Fund Management Co. Ltd. purchased a new position in Day One Biopharmaceuticals during the fourth quarter valued at $143,000. KLP Kapitalforvaltning AS bought a new stake in Day One Biopharmaceuticals in the fourth quarter worth $150,000. Finally, Optimize Financial Inc bought a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at $196,000. 87.95% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, CEO Jeremy Bender sold 12,048 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the transaction, the chief executive officer now directly owns 128,015 shares of the company's stock, valued at approximately $1,531,059.40. The trade was a 8.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. The trade was a 10.50 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,064 shares of company stock worth $251,925. Company insiders own 6.20% of the company's stock.
Day One Biopharmaceuticals Price Performance
Shares of DAWN traded down $0.31 on Friday, reaching $6.45. The company's stock had a trading volume of 1,335,859 shares, compared to its average volume of 1,078,881. The stock's 50 day simple moving average is $7.70 and its two-hundred day simple moving average is $11.08. The stock has a market capitalization of $653.78 million, a P/E ratio of -6.26 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a 12-month low of $6.26 and a 12-month high of $17.14.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.11. The company had revenue of $30.76 million during the quarter, compared to the consensus estimate of $30.28 million. Analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.
Analysts Set New Price Targets
DAWN has been the topic of a number of analyst reports. Wedbush reiterated an "outperform" rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday. JPMorgan Chase & Co. lowered their price objective on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 5th. HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. The Goldman Sachs Group lowered their price target on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a report on Tuesday, March 25th. Finally, Needham & Company LLC decreased their target price on Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $30.57.
Check Out Our Latest Report on DAWN
About Day One Biopharmaceuticals
(
Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
See Also
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
